Abstract
Introduction
Sepsis in human beings is a serious and often life-threatening situation that involves nearly 600,000 patients in North America, with a death rate approaching 50% [1] [2] [3] [4] [5] [6] 
. Besides supportive therapy (fluid resuscitation, ventilatory support and related treatments) and specific therapy (broad spectrum antibiotics), there is only one FDAapproved drug: recombinant activated protein C (APC). APC causes modest improvements in survival but has a central drawback. It is an anti-coagulant that is used in the setting of sepsis, which per se is associated with intrinsic coagulant changes (consumptive coagulopathy). Accordingly, therapeutic use of APC carries with it potentially life-threatening complications of haemorrhage and is a reason for the strict limitations in its use in septic human beings.
Sepsis has been classified clinically as: sepsis, severe sepsis, septic shock and multiorgan failure. There are, as yet, no specific markers for sepsis, although plasma levels of interleukin (IL)-6 and procalcitonin tend to correlate with the intensity of sepsis, but these biomarkers are entirely non-specific biomarkers of sepsis.
Their plasma presence occurs after trauma and a variety of other conditions. Clearly, we do not know enough about the fundamentals of sepsis to adequately understand what is happening. Why is sepsis occurring, and how can the progression to the more serious stages of sepsis be stopped or reversed? In this review we will focus chiefly on animal models of sepsis and what has been
learned from animal studies, mostly involving rodents. We will also emphasize the role of the complement system in sepsis and the fact the experimental sepsis converts a regulated inflammatory response into a completely dysregulated inflammatory condition. [14] . Details of how excessive levels of C5a are highly harmful are described below. [15] Fig. 1 Fig. 2  and [14] ). Limited amounts of C5a will also activate the PI3K and Akt signalling pathways (Fig. 2) [19, 20] . In CLP-induced sepsis, in vivo blockade of C5a greatly reduces the development of resistance of blood PMNs to apoptosis [19] . In sepsis there is intense activation of coagulation pathways (Fig. 2) (Fig. 3, [22] ). Up-regulation of ␤1 and ␤2
Models of sepsis

Sepsis as a dysfunctional inflammatory state
It has been known for some time that sepsis in human beings or animals exhibits evidence suggesting that regulation of the inflammatory response has been lost, resulting in high levels of proinflammatory mediators (IL-1␤, tumour necrosis factor [TNF]-␣, IL-6, IL-8, etc.) in plasma. This has been referred to as the 'systemic inflammatory response syndrome' (SIRS) [14]. The precise reasons for the high blood levels of these inflammatory mediators are not understood and the extent to which these mediators are responsible for multi-organ damage is still a matter of speculation. Over time during sepsis, there is often the presence of antiinflammatory mediators (e.g. IL-10, IL-12, IL-13), originally considered to be a response to the earlier appearing pro-inflammatory mediators of SIRS. This situation was described by R. Bone to be a 'compensatory anti-inflammatory response syndrome' (CARS)
Protective effects of C5a generated in limited amounts
To put C5a into a biological perspective, if the amount of C5a generated locally (as at a site of bacterial infection) is limited (Յ10 nM), remaining in the physiological range, there will be several beneficial effects as described in
Sepsis-induced changes in signalling cascades
(CCL-2), MCP-2 (CCL-4), MCP-3 (CCL-7) and MCP-4 (CCL-12)
integrins (the latter of which binds to ICAM-1 and iC3b) as well as expression of CCR-2 implies that PMNs now have a 'gain of function', such that they can more robustly bind to ligands as well as being able to respond to ligands that they usually do not recognize. Collectively, blood PMNs and endothelial cells are converted to a pro-inflammatory state during CLP-induced sepsis,
Fig. 1 Effects of physiological levels of C5a (circa 10nM) on neutrophils, monocytes/macrophages and endothelial cells. The responses of the various cell types result in enhanced innate immune responses to infectious agents. which may put tissues at risk of injury due to an intensified inflammatory response.
Divergent effects on phagocytic cells during sepsis
During CLP-induced sepsis in rats, excessive production of C5a can lead to signalling paralysis of blood PMNs, resulting in loss of
protective innate immune functions [14] . Table 1 
summarizes studies in which blood PMNs, peripheral blood mononuclear cells (PBMCs) and alveolar macrophages were isolated and compared for functional responses before and after onset of sepsis (CLP). As has been shown in many different studies of sepsis in animals and in human beings, the innate immune responses of blood PMNs were defective. Chemotaxis (to C5a and to a chemically unrelated peptide, N-formyl Met Leu Phe) was defective, phagocytosis was
Fig. 2 Signalling pathway activation by C5a on neutrophils, monocytes/macrophages and endothelial cells, resulting in compromised innate immunity, resistance of neutrophils to apoptosis, a cytokine storm and disseminated intravascular coagulation.
Fig. 3 Perturbations in blood neutrophils during sepsis, resulting in the appearance of high levels of CCR-2, which now allows cells to respond to MCP-1 (CCR-2) and related ligands. This represents a 'gain of function' for neutrophils.
depressed and the respiratory burst (H2O2 production) was impaired [14] . The last abnormality was due to a C5a-induced defect in the ability of stimulated PMNs to translocate cytosolic subunits (p47 phox ) of NADPH oxidase to the cell membrane where full assembly and activation of the oxidase takes place [14] . The effects on functional innate immune parameters in PBMCs and alveolar macrophages remain to be determined.
When cytokine and chemokine production was assessed in vitro following in vitro incubation of leucocytes with LPS, mediator production was suppressed in PMNs and PBMCs but enhanced in alveolar macrophages [23]. Finally, in a similar manner, LPS-induced activation (phosphorylation) of the MAPK, ERK1/2, was depressed in blood PMNs but enhanced in lung macrophages in the setting of CLP-induced sepsis. These data suggest, in general, that there is a loss in function involving blood PMNs and PBMCs and a gain in function in lung macrophages. Either lung macrophages cannot be rendered functionally defective by exposure to C5a, or the amounts of C5a to which lung macrophages are exposed after CLP is much lower than C5a levels in blood, resulting in priming of lung macrophages. It is not clear why there are such dramatic differences in functional responses of phagocytic cells based on their location (vascular versus extravascular) during sepsis.
Harmful effects of C5a and C5a receptors in experimental sepsis
As has been alluded to above, there are many harmful outcome related to interaction of C5a with its receptors during sepsis. As described above, considerable C5a is generated during sepsis and appears within the vascular compartment, reaching plasma concentrations as high as 100 nM [24] . C5a receptors on PMNs and in tissues are in a dynamic state after CLP. In general, mRNA and protein for C5aR are up-regulated in a variety of organs (lung, heart, kidney, liver) [25] . It appears that up-regulation of C5L2 also occurs, but not as robustly when compared to C5aR [25] . Figure 4 [16] [17] [18] . [26, 27] . Our own studies have shown in CLP rats that the thymus undergoes massive apoptosis that is both C5a and C5aR dependent [28] . Within 3 hrs after CLP, thymocytes bind higher amounts of C5a (due to increased C5aR protein on surfaces of thymocytes) and can be shown to undergo apoptosis in vitro after the addition of C5a [28] . Apoptosis is associated with engagement of the intrinsic (mitochondrial) apoptotic pathway featuring activation of caspases 3, 6 and 9. When anti-C5a is given at the time of CLP, caspase activation and apoptosis in thymocytes are greatly reduced [28] . There is other evidence that the extrinsic pathway of apoptosis is also engaged after CLP in mice, as defined by the requirements for Fas and Fas ligand [29, 30] .
summarizes the results of C5a interacting with its receptors after CLP. As described above, C5a binding with C5aR on PMNs leads to MAPK signalling paralysis in these cells, resulting in loss of innate immune functions. The outcome is loss of protective functions of PMNs and attendant lethal bacteraemia. The upregulation on blood PMN surfaces of CD18 indicates that these cells have been activated. Increased expression of IL-6, IL-8, etc. by endothelial cells implies that adherent PMNs will be activated after contact with IL-6 and IL-8. C5a interaction with tissue macrophages appears to be linked to development of the SIRS of sepsis, due to priming of these cells and the resulting surge of pro-inflammatory cytokines and chemokines in plasma and in tissues. To what extent the presence of these mediators can be directly linked to harmful events such as multi-organ damage and failure is currently a matter of much debate. The interaction of endothelial cells with C5a via interaction with C5aR results in a pro-inflammatory state that can be linked to chemokine expression and induction of tissue factor, the latter contributing to disseminated intravascular coagulation, consumptive coagulopathy and formation of intravascular thrombi
Development of immunosuppression during sepsis is well documented and has been assumed to be the result of apoptosis of lymphoid cells (both T and B cells) and the ensuing development of the immunosuppression of sepsis
We have recently shown that adrenal medullary cells also undergo apoptosis during sepsis [31] . This would imply that the major source of catecholamines (epinephrine and norepinephrine) is lost during sepsis, compromising the ability to sustain adequate blood pressure for tissue perfusion. During sepsis, it is well described that the 'cardiomyopathy of sepsis' develops, which refers to falling cardiac output, diminished blood pressure and declining vascular perfusion (Fig. 4) 
